Daré Bioscience (DARE) Registration filing summary

Company overview and business model

• Focuses on women's health, advancing products from contraception to menopause, sexual health, fertility, and infectious disease.

• Employs a dual-path strategy: traditional FDA approval and earlier market access via Section 503B compounding for select proprietary formulations.

• Launched first compounded drug (DARE to PLAY Sildenafil Cream) in December 2025, with revenue expected in Q3 2026; also introduced a consumer health probiotic in June 2026.

• Pipeline includes clinical and preclinical candidates, with Ovaprene (contraceptive) in Phase 3 and other products targeting menopause, sexual dysfunction, and HPV.

• Relies on third-party outsourcing for manufacturing and distribution, with limited internal sales infrastructure.

Financial performance and metrics

• Recent offerings raised approximately $5.3 million in net proceeds from a registered direct offering and private placement in August 2026.

• Ongoing need for substantial additional capital to fund operations and execute business strategy.

• Financial statements include a going concern warning from auditors due to uncertainty about continued operations.

Use of proceeds and capital allocation

• Proceeds from warrant exercises (up to $12.4 million if fully exercised) will be used for working capital, general corporate purposes, 503B compounding, consumer health strategies, R&D, and administrative costs.

• No proceeds from resale of shares by selling stockholders; only from cash warrant exercises.